According to Klein’s analysis, pathogenic variants in the CDKN2A gene, initially linked to melanoma susceptibility, have also been implicated in pancreatic cancer risk, and carriers of CDKN2A mutations exhibit a substantial 12–38-fold increased risk of developing pancreatic cancer, with a prevalence of up to 2.5% in familial cases. This evidence concerns the gene CDKN2A and melanoma.